François M. Castonguay and James N. Sanchirico, and coauthors have a preprint on COVID-19 vaccine and antivirals allocation. Much of the discussion around pharmaceutical interventions for COVID-19 has focused on what segments of the population to prioritize for vaccines. Questions on how to allocate a vaccine across jurisdictions within a country and how to allocate other pharmaceutical interventions, such as antiviral drugs have received much less attention. The paper investigates these questions by benchmarking the economic and public health performance of ad hoc allocation rules against optimally-derived rules. The paper measures the robustness of these rules to compliance to non-pharmaceutical interventions, such as travel restrictions, and to uncertainty on the degree of immunity. François, Jim and coauthors find economic and public health gains from spatially targeted rules even after considering additional costs associated with deviations from the ad hoc rules.